Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2012, Article ID 496453, 8 pages
http://dx.doi.org/10.1100/2012/496453
Clinical Study

The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone

1Department of Gastroenterology, Mitsui Memorial Hospital, Kanda-izumicho 1, Chiyoda-ku, Tokyo 101-8643, Japan
2Department of Diabetes and Metabolism, Mitsui Memorial Hospital, Kanda-izumicho 1, Chiyoda-ku, Tokyo 101-8643, Japan
3Department of Gastroenterology, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
4Yamanashi Prefectural Hospital Organization, 1-1-1 Fujimi, Kofu City 400-8506, Japan

Received 29 May 2012; Accepted 12 July 2012

Academic Editors: H. L. Y. Chan, C. Trepo, and L. A. Videla

Copyright © 2012 Takamasa Ohki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [40 citations]

The following is the list of published articles that have cited the current article.

  • Manhal Olaywi, Taruna Bhatia, Sury Anand, and Shashideep Singhal, “Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review,” Hepatobiliary & Pancreatic Diseases International, vol. 12, no. 6, pp. 584–588, 2013. View at PublisherView at Google Scholar
  • Susan L. Samson, and Mandeep Bajaj, “Potential of incretin-based therapies for non-alcoholic fatty liver disease,” Journal of Diabetes and its Complications, 2013. View at PublisherView at Google Scholar
  • Manhal Olaywi, Taruna Bhatia, Sury Anand, and Shashideep Singhal, “Novel anti-diabetic agents in non-alcoholic fatty liver disease: A mini-review,” Hepatobiliary and Pancreatic Diseases International, vol. 12, no. 6, pp. 584–588, 2013. View at PublisherView at Google Scholar
  • Tomoya Umezono, Naoyuki Yamamoto, Masao Toyoda, Masaaki Miyauchi, Hiroki Sato, Eitaro Tanaka, Han Miyatake, Moritugu Kimura, Daisuke Suzuki, Makiko Abe, Masafumi Fukagawa, and Yusuke Kuriyama, “Effects of Liraglutide, a Human Glucagon-like Peptide-1 Analogue, on Body Weight, Body Fat Area and Body Fat-related Markers in Patients with Type 2 Diabetes Mellitus,” Internal Medicine, vol. 52, no. 10, pp. 1029–1034, 2013. View at PublisherView at Google Scholar
  • André J. Scheen, “Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus,” Clinical Pharmacokinetics, 2014. View at PublisherView at Google Scholar
  • Kristina Blaslov, Tomislav Bulum, Karin Zibar, and Lea Duvnjak, “Incretin based therapies: A novel treatment approach for non-alcoholic fatty liver disease,” World Journal of Gastroenterology, vol. 20, no. 23, pp. 7356–7365, 2014. View at PublisherView at Google Scholar
  • Yuichiro Eguchi, Yoichiro Kitajima, Hideyuki Hyogo, Hirokazu Takahashi, Motoyasu Kojima, Masafumi Ono, Norimasa Araki, Kenichi Tanaka, Miyuki Yamaguchi, Yayoi Matsuda, Yasushi Ide, Taiga Otsuka, Iwata Ozaki, Naofumi Ono, Takahisa Eguchi, and Keizo Anzai, “Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J),” Hepatology Research, 2014. View at PublisherView at Google Scholar
  • André J Scheen, “Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease,” Expert Opinion on Drug Metabolism & Toxicology, pp. 1–19, 2014. View at PublisherView at Google Scholar
  • Manfredi Rizzo, Giuseppe Montalto, and Khalid Al-Rasadi, “Treatment options for managing atherogenic dyslipidemia and fatty liver disease,” Expert Opinion on Pharmacotherapy, pp. 1–4, 2014. View at PublisherView at Google Scholar
  • Fen Xu, Zhuo Li, Xiaobin Zheng, Hongxia Liu, Hua Liang, Haixia Xu, Zonglan Chen, Kejing Zeng, and Jianping Weng, “SIRT1 Mediates the Effect of GLP-1 Receptor Agonist Exenatide on Ameliorating Hepatic Steatosis,” Diabetes, vol. 63, no. 11, pp. 3637–3646, 2014. View at PublisherView at Google Scholar
  • Stefano Ballestri, Giovanni Targher, Paola Loria, and Amedeo Lonardo, “Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease,” Expert Review of Gastroenterology & Hepatology, pp. 1–22, 2014. View at PublisherView at Google Scholar
  • Xing-Chun Wang, Aaron M. Gusdon, Huan Liu, and Shen Qu, “Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation,” World Journal of Gastroenterology, vol. 20, no. 40, pp. 14821–14830, 2014. View at PublisherView at Google Scholar
  • Theodora Nakouti, Konstantinos Tziomalos, Apostolos K.A. Karagiannis, and Evangelos Cholongitas, “Incretin-based antidiabetic agents for the management of non-alcoholic fatty liver disease,” Current Vascular Pharmacology, vol. 13, no. 5, pp. 649–657, 2015. View at PublisherView at Google Scholar
  • Ali A Rizvi, Angelo Maria Patti, Rosaria Vincenza Giglio, Dragana Nikolic, Antonella Amato, Noor Al-Busaidi, Khalid Al-Rasadi, Maurizio Soresi, Maciej Banach, Giuseppe Montalto, and Manfredi Rizzo, “Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study,” Expert Opinion on Biological Therapy, pp. 1–7, 2015. View at PublisherView at Google Scholar
  • Elena Pavlova Filipova, Katya Hristova Uzunova, and Toni Yonkov Vekov, “Comparative analysis of therapeutic efficiency and costs (experience in Bulgaria) of oral antidiabetic therapies based on glitazones and gliptins,” Diabetology & Metabolic Syndrome, vol. 7, no. 1, 2015. View at PublisherView at Google Scholar
  • Chao-lin Li, Lu-jie Zhao, Xin-li Zhou, Hui-xiao Wu, and Jia-jun Zhao, “Review on the effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non-alcoholic fatty liver disease,” Journal of Huazhong University of Science and Technology [Medical Sciences], vol. 35, no. 3, pp. 333–336, 2015. View at PublisherView at Google Scholar
  • Harikrashna B Bhatt, and Robert J Smith, “Fatty liver disease in diabetes mellitus.,” Hepatobiliary surgery and nutrition, vol. 4, no. 2, pp. 101–8, 2015. View at PublisherView at Google Scholar
  • Laura J Carbone, Peter W Angus, and Neville D Yeomans, “Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis,” Journal of Gastroenterology and Hepatology, vol. 31, no. 1, pp. 23–31, 2015. View at PublisherView at Google Scholar
  • Wenjuan Tang, Qianyue Xu, Ting Hong, Guoyu Tong, Wenhuan Feng, Shanmei Shen, Yan Bi, and Dalong Zhu, “Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies,” Diabetes/Metabolism Research and Reviews, 2015. View at PublisherView at Google Scholar
  • Diego García-Compeán, José A. González-González, Fernando J. Lavalle-González, Emmanuel I. González-Moreno, Héctor J. Maldonado-Garza, and Jesús Z. Villarreal-Pérez, “The treatment of diabetes mellitus of patients with chronic liver disease,” Annals of Hepatology, vol. 14, no. 6, pp. 780–788, 2015. View at PublisherView at Google Scholar
  • Diego García-Compeán, José Alberto González-González, Fernando Javier Lavalle-González, Emmanuel Irineo González-Moreno, Jesús Zacarías Villarreal-Pérez, and Héctor J. Maldonado-Garza, “Current Concepts in Diabetes Mellitus and Chronic Liver Disease: Clinical Outcomes, Hepatitis C Virus Association, and Therapy,” Digestive Diseases and Sciences, 2015. View at PublisherView at Google Scholar
  • Gregor Lorbek, Žiga Urlep, and Damjana Rozman, “Pharmacogenomic and personalized approaches to tackle the nonalcoholic fatty liver disease,” Pharmacogenomics, 2016. View at PublisherView at Google Scholar
  • Amrita Ostawal, Emina Mocevic, Nana Kragh, and Weiwei Xu, “Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review,” Diabetes Therapy, 2016. View at PublisherView at Google Scholar
  • Gautam Das, and Hemanth Bolusani, “Hepatitis C virus infection and diabetes,” Practical Diabetes, vol. 33, no. 4, pp. 123–128b, 2016. View at PublisherView at Google Scholar
  • Diana Barb, Paola Portillo-Sanchez, and Kenneth Cusi, “Pharmacological Management of Nonalcoholic Fatty Liver Disease,” Metabolism, 2016. View at PublisherView at Google Scholar
  • Paola Portillo-Sanchez, and Kenneth Cusi, “Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus,” Clinical Diabetes and Endocrinology, vol. 2, no. 1, 2016. View at PublisherView at Google Scholar
  • Takamasa Ohki, Akihiro Isogawa, Nobuo Toda, and Kazumi Tagawa, “Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors,” Clinical Drug Investigation, 2016. View at PublisherView at Google Scholar
  • Floriana Elvira Ionică, Simona Negreș, Ludovic Bejenaru, Cornelia Bejenaru, and Cornel Chiriță, “Pharmacological Approaches for Nonalcoholic Fatty Liver Disease,” Romanian Journal of Diabetes Nutrition and Metabolic Diseases, vol. 23, no. 3, 2016. View at PublisherView at Google Scholar
  • Mark M Smits, Daniel H van Raalte, Lennart Tonneijck, Marcel H A Muskiet, Mark H H Kramer, and Djuna L Cahen, “GLP-1 based therapies: clinical implications for gastroenterologists,” Gut, vol. 65, no. 4, pp. 702–711, 2016. View at PublisherView at Google Scholar
  • Gauri Dhir, and Kenneth Cusi, “Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option,” Journal of Investigative Medicine, vol. 66, no. 1, pp. 7–10, 2017. View at PublisherView at Google Scholar
  • Kenneth Cusi, “Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes,” Diabetes and Exercise, pp. 47–69, 2017. View at PublisherView at Google Scholar
  • Luigi Barrea, Carolina Di Somma, Giovanna Muscogiuri, Giovanni Tarantino, Gian Carlo Tenore, Francesco Orio, Annamaria Colao, and Silvia Savastano, “Nutrition, inflammation and liver-spleen axis,” Critical Reviews in Food Science and Nutrition, pp. 00–00, 2017. View at PublisherView at Google Scholar
  • Kalyan Kumar Gangopadhyay, and Parminder Singh, “Consensus statement on dose modifications of antidiabetic agents in patients with hepatic impairment,” Indian Journal of Endocrinology and Metabolism, vol. 21, no. 2, pp. 341–354, 2017. View at PublisherView at Google Scholar
  • Yoshio Sumida, Yuya Seko, and Masashi Yoneda, “Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus,” Hepatology Research, vol. 47, no. 4, pp. 266–280, 2017. View at PublisherView at Google Scholar
  • Yajie Dong, Qingguo Lv, Sheyu Li, Yuan Wu, Ling Li, Juan Li, Fang Zhang, Xin Sun, and Nanwei Tong, “Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis,” Clinics and Research in Hepatology and Gastroenterology, 2017. View at PublisherView at Google Scholar
  • Ayman Geddawy, Marwa Hussian, Mohamed A. Ibrahim, Maha Yehia Kamel, and Rehab Kamal, “Effects of liraglutide and Vitamin E in fructose-induced metabolic syndrome in rats,” Pharmacology, vol. 99, no. 1-2, pp. 48–56, 2017. View at PublisherView at Google Scholar
  • Saba Sayari, Hassan Neishaboori, and Maryam Jameshorani, “Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease,” Clinical and Molecular Hepatology, 2018. View at PublisherView at Google Scholar
  • S. Spahis, F. Alvarez, N. Ahmed, J. Dubois, R. Jalbout, M. Paganelli, K. Grzywacz, E. Delvin, N. Peretti, and Emile Levy, “Non-Alcoholic fatty liver disease severity and metabolic complications in obese children: Impact of Omega-3 Fatty Acids,” The Journal of Nutritional Biochemistry, 2018. View at PublisherView at Google Scholar
  • Titli Nargis, and Partha Chakrabarti, “Significance of circulatory DPP4 activity in metabolic diseases,” IUBMB Life, 2018. View at PublisherView at Google Scholar
  • Julia Wattacheril, Danny Issa, and Arun Sanyal, “Nonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies,” Annual Review of Pharmacology and Toxicology, vol. 58, no. 1, pp. 649–662, 2018. View at PublisherView at Google Scholar